RNAi Therapeutics
•24 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (24)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
RNAi therapeutics are part of Lilly's genetic medicine push.
|
$956.21B |
$1007.10
-0.73%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
C5 siRNA program represents RNA interference therapeutics in Regeneron’s genetic medicines portfolio.
|
$76.14B |
$721.57
-0.17%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$60.05B |
$459.11
-1.34%
|
|
RNA
Avidity Biosciences, Inc.
RNA interference (siRNA) payloads are part of the therapeutic approach described (AOC delivering RNA-based payloads).
|
$9.22B |
$71.73
+0.27%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$8.49B |
$61.41
-5.03%
|
|
CRSP
CRISPR Therapeutics AG
SRSD107 is an RNA interference therapeutic, aligning with the RNAi Therapeutics category.
|
$5.17B |
$56.78
-2.41%
|
|
APLS
Apellis Pharmaceuticals, Inc.
APLJ? APL-3007 is an siRNA therapeutic targeting FcRn, placing the program under the RNAi Therapeutics theme.
|
$2.98B |
$24.00
+8.16%
|
|
SRPT
Sarepta Therapeutics, Inc.
siRNA platform (TRiM) with Arrowhead collaboration positions Sarepta in RNA interference therapeutics.
|
$2.18B |
$22.27
-2.41%
|
|
AGIO
Agios Pharmaceuticals, Inc.
AG-236 is an siRNA (RNAi) therapeutic in preclinical development, fitting RNAi therapeutics as a major modality in Agios's pipeline.
|
$1.61B |
$27.91
+1.79%
|
|
WVE
Wave Life Sciences Ltd.
WVE-007 includes an siRNA (RNA interference) program, making RNAi therapeutics a core modality for the company.
|
$1.19B |
$7.50
-1.51%
|
|
QURE
uniQure N.V.
miQURE silencing technology enables RNA interference-based therapeutics, placing the company in the RNAi therapeutics modality.
|
$1.17B |
$21.33
-6.20%
|
|
VIR
Vir Biotechnology, Inc.
Elebsiran is an RNA interference (RNAi) therapeutic, placing Vir in RNAi Therapeutics.
|
$902.96M |
$6.50
-4.13%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$847.31M |
$4.34
-1.47%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT's RNA interference modality (RNAi therapeutics) aligns with a gene-silencing oligonucleotide approach described in the program.
|
$499.72M |
$10.85
-3.04%
|
|
BNTC
Benitec Biopharma Inc.
Benitec's ddRNAi approach centers on RNA interference therapeutics, placing it under RNAi Therapeutics.
|
$356.48M |
$13.42
+1.82%
|
|
SLN
Silence Therapeutics plc
Silence Therapeutics directly develops RNA interference therapeutics (siRNA) as its core product modality.
|
$328.29M |
$7.00
-1.89%
|
|
VYGR
Voyager Therapeutics, Inc.
VY1706 uses siRNA payload delivered via TRACER capsids, mapping to RNAi Therapeutics.
|
$237.41M |
$4.29
-1.38%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$165.19M |
$1.80
+1.98%
|
|
ALEC
Alector, Inc.
ADP064-ABC includes an anti-tau siRNA program, representing RNA interference therapeutics.
|
$123.48M |
$1.23
+1.65%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$35.16M |
$5.31
+1.72%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-KIT is described as a precision antisense therapy, aligning with RNAi therapeutics.
|
$15.91M |
$1.21
+1.26%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is based on RNA interference (siRNA), making RNAi therapeutics a core product/framework.
|
$7.50M |
$1.34
-0.37%
|
|
RNAZ
TransCode Therapeutics, Inc.
Company focuses on RNA interference (RNAi) therapeutics, including siRNA/miRNA-targeted programs.
|
$7.18M |
$8.56
-0.88%
|
|
RGBP
Regen BioPharma, Inc.
DiffronC is described as an in vivo siRNA therapy, placing RGBP in the RNAi Therapeutics space.
|
$302925 |
$0.01
|
Loading company comparison...
Loading industry trends...
Loading research report...
